Advances in pulmonary therapy

Advanced Drug Formulation Design to Optimize Therapeutic Outcomes

Volumn , Issue , 2007, Pages 1-52

  Young, Paul M ^a   Traini, Daniela ^a   Edge, Stephen ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955607003     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Versteeg HK, Hargrave G. Fundamentals and resilience of the original MDI actuator design. Proc Respir Drug Deliv 2006; 1:91–100.
2. Anderson PJ2005. History of aerosol therapy: liquid nebulization to MDIs to DPIs. Respir Care 2005; 50:1139–50.
3. Patton JS. Mechanisms of macromolecule absorption by the lungs. Adv Drug Deliv Rev 1996; 19:3–36.
4. Pritchard JN2001. The influence of lung deposition on clinical response 1. J Aerosol Med Deposit Clearance Eff Lung 2001; 14:S19–26.
5. Yeh HC, Schum GM. Models of human-lung airways and their application to inhaled particle deposition. Bull Math Biol 1980; 42:461–80.
6. Schum M, Yeh HC. Theoretical evaluation of aerosol eeposition in anatomical models of mammalian lung airways. Bull Math Biol 1980; 42:1–15.
7. Hinds WC. Aerosol Technology, 2nd ed. New York: John Willey & Sons; 1999.
8. Findeisen W. The precipitation of small air-suspended particles in human lungs during respiration. Pflugers Arch Die Gesamte Physiol Menschen Tiere 1935; 236:367–79.
9. Ferron GA. Aerosol properties and lung deposition. Eur Respir J 1994; 7:1392–4.
10. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys 1966; 12: 173–207.
11. Smith IJ, Parry-Billings M. The inhalers of the future? A review of dry powder devices on the market today. Pulm Pharmacol Ther 2003; 16:79–95.
12. Franks F1999. Thermomechanical properties of amorphous saccharides: Their role in enhancing pharmaceutical product stability. Biotechnol Genet Eng Rev 1999; 16:281–92.
13. Ò: Pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 2005; 7:896–906.
14. Duddu SP, Sisk SA, Walter YH, et al. Improved lung delivery from a passive dry powder inhaler using an engineered PulmoSphere (R) powder. Pharm Res 2002; 19:689–95.
15. Edwards DA, Hanes J, Caponetti G, et al. Large porous particles for pulmonary drug delivery. Science 1997; 276:1868–71.
16. Hersey JA. Ordered Mixing–New Concept in Powder Mixing Practice 17. Powder Technol 1975; 11:41–4.
17. Staniforth JN. Order out of chaos. J Pharm Pharm 1987; 39:329–34.
18. Timsina MP, Martin GP, Marriott C, Ganderton D, Yianneskis M1994. Drug-delivery to the respiratory-tract using dry powder inhalers. Int J Pharm 1994; 101:1–13.
19. Coates MS, Fletcher DF, Chan HK, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci 2004; 93:2863–76.
20. Srichana T, Martin GP, Marriott C. Dry powder inhalers: The influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998; 7:73–80.
21. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20:886–98.
22. Flament MP, Leterme P, Gayot A. The influence of carrier roughness on adhesion, content uniformity and the in vitro deposition of terbutaline sulphate from dry powder inhalers 19. Int J Pharm 2004; 275:201–9.
23. Kawashima Y, Serigano T, Hino T, Yamamoto H, Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int J Pharm 1998; 172:179–88.
24. Zeng XM, Martin GP, Marriott C, Pritchard J. Lactose as a carrier in dry powder formulations: The influence of surface characteristics on drug delivery. J Pharm Sci 2001; 90:1424–34.
25. Ferrari F, Cocconi D, Bettini Ret al. 2004. The surface roughness of lactose particles can be modulated by wet-smoothing using a high-shear mixer. AAPS PharmSciTech 2004; 5:1–6.
26. Young PM, Cocconi D, Colombo P, et al. 2002. Characterization of a surface modified dry powder inhalation carrier prepared by “particle smoothing”. J Pharm Pharm 2002; 54:1339–44.
27. Iida K, Hayakawa Y, Okamoto H, Danjo K, Leuenberger H. Preparation of dry powder inhalation by surface treatment of lactose carrier particles. Chem Pharm Bull 2003; 51:1–5.
28. El-Sabawi D, Price R, Edge S, Young PM. Novel temperature controlled surface dissolution of excipient particles for carrier based dry powder inhaler formulations 1. Drug Dev Ind Pharm 2006; 32:243–51.
29. Zeng XM, Martin GP, Marriott C, Pritchard J. The influence of carrier morphology on drug delivery by dry powder inhalers. Int J Pharm 2000; 200: 93–106.
30. Staniforth JN. Pre-formulation Aspects of Dry Powder Aerosols. Proc Respir Drug Deliv 1996; 1:65–73.
31. El-Sabawi D, Edge S, Price R, Young P. Continued investigation into the influence of loaded dose on the performance of dry powder inhalers: surface smoothing effects. Drug Dev Ind Pharm 2006; 32:1135–8.
32. Young PM, Edge S, Traini D, et al. The influence of dose on the performance of dry powder inhalation systems 1. Int J Pharm 2005; 296:26–33.
33. Begat P, Morton DAV, Staniforth JN, Price R. The cohesive-adhesive balances in dry powder inhaler formulations II: Influence on fine particle delivery characteristics. Pharm Res 2004; 21:1826–33.
34. Begat P, Morton DAV, Staniforth JN, Price R. The cohesive-adhesive balances in dry powder inhaler formulations I: Direct quantification by atomic force microscopy. Pharm Res 2004; 21:1591–7.
35. Ahfat NM, Buckton G, Burrows R, Ticehurst MD. Predicting mixing performance using surface energy measurements. Int J Pharm 1997; 156:89–95.
36. Louey MD, Razia S, Stewart PJ. Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures 3. Int J Pharm 2003; 252:87–98.
37. Islam N, Stewart P, Larson I, Hartley P. Effect of carrier size on the dispersion of salmeterol xinafoate from interactive mixtures. J Pharm Sci 2004; 93:1030–8.
38. Islam N, Stewart P, Larson I, Hartley P. Lactose surface modification by decantation: Are drug-fine lactose ratios the key to better dispersion of salmeterol xinafoate from lactose-interactive mixtures? 2. Pharmaceutical Research 2004; 21:492–9.
39. Adi H, Larson I, Chiou H, Young P, Traini D, Stewart P. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm Res 2006; 23:2556–65.
40. Steckel H, Markefka P, teWierik H, Kammelar R. Effect of milling and sieving on functionality of dry powder inhalation products. Int J Pharm 2006; 309:51–9.
41. Young PM, Traini D, Chan HK, Chiou H, Edge S, Tee T. The influence of mechanical processing dry powder inhaler carriers on drug aerosolisation performance. J Pharm Sci 2007; in press.
42. Lucas P, Anderson K, Staniforth JN. Protein deposition from dry powder inhalers: Fine particle multiplets as performance modifiers. Pharm Res 1998; 15:562–9.
43. Louey MD, Stewart PJ. Particle interactions involved in aerosol dispersion of ternary interactive mixtures 5. Pharm Res 2002; 19:1524–31.
44. Handoko A, Ian L, Herbert C, Paul Y, Daniela T, Peter S. Agglomerate strength and dispersion of salmeterol xinafoate from powder mixtures for inhalation. Pharm Res 2006; V23:2556–65.
45. Jones MD, Price R. The influence of fine excipient particles on the performance of carrier-based dry powder inhalation formulations. Pharm Res 2006; 23:1665–74.
46. Tee SK, Marriott C, Zeng XM, Martin GP. The use of different sugars as fine and coarse carriers for aerosolised salbutamol sulphate. Int J Pharm 2000; 208: 111–23.
47. Steckel H, Bolzen N. Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 2004; 270:297–306.
48. Hooton JC, Jones MD, Price R. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive-adhesive force balance approach. J Pharm Sci 2006; 95:1288–97.
49. Traini D, Young PM, Jones MD, Edge S, Price R. Comparative study of erythritol and lactose monohydrate as carriers for inhalation: Atomic force microscopy and in vitro correlation. Eur J Pharm Sci 2006; 27:243–51.
50. Steckel H, Markefka P, teWierik H, Kammelar R. Functionality testing of inhalation grade lactose 12. Eur J Pharm Biopharm 2004; 57:495–505.
51. Zeng XM, Martin GP, Marriott C, Pritchard J. The use of lactose recrystallised from carbopol gels as a carrier for aerosolised salbutamol sulphate. Eur J Pharm Biopharm 2001; 51:55–62.
52. Iida K, Hayakawa Y, Okamoto H, Danjo K, Luenberger H. Effect of surface layering time of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate. Chem Pharm Bull 2004; 52:350–3.
53. Begat P, Price R, Harris H, Morton DAV, Staniforth JN. The influence of force control agents on the cohesive-adhesive balance in dry powder inhaler formulations. KONA 2005; 23:109–21.
54. Lucas P, Anderson K, Potter UJ, Staniforth JN. Enhancement of small particle size dry powder aerosol formulations using an ultra low density additive. Pharm Res 1999; 16:1643–7.
55. Kumon M, Suzuki M, Kusai A, Yonemochi E, Terada K. Novel approach to DPI carrier lactose with mechanofusion process with additives and evaluation by IGC. Chem Pharm Bull 2006; 54:1508–14.
56. Anon. Beclometasone Pulvinal product data sheet., http://www.trinity-chiesi. co.uked.; 2007.
57. Iida K, Hayakawa Y, Okamoto H, Danjo K, Luenberger H. Influence of storage humidity on the in vitro inhalation properties of salbutamol sulfate dry powder with surface covered lactose carrier. Chem Pharm Bull 2004; 52:444–6.
58. Begat P, Green M, Morton D, Whittock A, Staniforth JN. PowderHale: A novel high performance dry powder inhaler formulation technology for targeted and systemic drug delivery. Proc Drug Deliv Drug Deliv Lung 2001; XII119.
59. Louey MD, Mulvaney P, Stewart PJ. Characterisation of adhesional properties of lactose carriers using atomic force microscopy 1. J Pharm Biomed Anal 2001; 25:559–67.
60. Berard V, Lesniewska E, Andres C, Pertuy D, Laroche C, Pourcelot Y. Affinity scale between a carrier and a drug in DPI studied by atomic force microscopy 1. Int J Pharm 2002; 247:127–37.
61. Young PM. Characterisation of particle-particle interactions using the atomic force microscope. U 2002; 1–187.
62. Ward GH, Schultz RK. Process-induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm Res 1995; 12:773–9.
63. Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 2006; 95:1641–65.
64. Buckton G, Darcy P. Assessment of disorder in crystalline powders—a review of analytical techniques and their application. Int J Pharm 1999; 179:141–58.
65. Handbook of Industrial Crystallization, 2nd ed., Boston, MA: Butterworth-Heinemann; 2002.
66. Jung J, Perrut M. Particle design using supercritical fluids: Literature and patent survey. J Supercrit Fluids 2001; 20:179–219.
67. Tong HHY, Shekunov BY, York P, Chow AHL. Influence of polymorphism on the surface energetics of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 2002; 19:640–8.
68. Tong HHY, Shekunov BY, York P, Chow AHL. Characterization of two polymorphs of salmeterol xinafoate crystallized from supercritical fluids. Pharm Res 2001; 18:852–8.
69. Shekunov BY, Feeley JC, Chow AHL, Tong HHY, York P. Aerosolisation behaviour of micronised and supercritically-processed powders. J Aerosol Sci 2003; 34:553–68.
70. Anon. Inhale announces that offer to acquire Bradford particle design plc has met conditions to close. Archived press releasesed; 2007.
71. Young PM, Price R. The influence of humidity on the aerosolisation of micronised and SEDS produced salbutamol sulphate. Eur J Pharm Sci 2004; 22:235–40.
72. Burnett DJ, Thielmann F, Booth J. Determining the critical relative humidity for moisture-induced phase transitions. Int J Pharm 2004; 287:123–33.
73. Kaerger JS, Price R. Processing of spherical crystalline particles via a novel solution atomization and crystallization by sonication (SAXS) technique. Pharm Res 2004; 21:372–81.
74. Chen JF, Zhou MY, Shao L, et al. Feasibility of preparing nanodrugs by high-gravity reactive precipitation. Int J Pharm 2004; 269:267–74.
75. Chan HK. Dry powder aerosol drug delivery—Opportunities for colloid and surface scientists. Colloids Surfaces A Physicochem Eng Aspects 2006; 284: 50–5.
76. Chiou H, Li T, Hu T, Chan HK, Chen J-F, Yon J. Production of salbutamol sulfate for inhalation by high-gravity controlled antisolvent precipitation. Int J Pharm 2007; 331:93–8.
77. Johnson BK, Prud’homme RK. Chemical processing and micromixing in confined impinging jets. AICHE J 2003; 49:2264–82.
78. Broadhead J, Rouan SKE, Rhodes CT. The spray drying of pharmaceuticals. Drug Dev Indl Pharm 1992; 18:1169–206.
79. Chew NYK, Tang P, Chan HK, Raper JA. How much particle surface corrugation is sufficient to improve aerosol performance of powders? Pharm Res 2005; 22:148–52.
80. Chew NYK, Chan HK. Use of solid corrugated particles to enhance powder aerosol performance. Pharm Res 2001; 18:1570–7.
81. Dellamary LA, Tarara TE, Smith DJ, et al. Hollow porous particles in metered dose inhalers. Pharm Res 2000; 17:168–74.
82. Weers JG. Dispersible powders for inhalation applications. Innov Pharm Tech 2000; 1:111–16.
83. Newman SP, BUSSE WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002; 96:293–304.
84. Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm 2004; 277:31–7.
85. Price R, Staniforth JN, Woodcock D, Young PM. Delivery device for a dry powder aerosol. PCT/GB2004/002490 ed. 2004; 1–49.
86. Thiel C. From Susie’s question to CFC free: An inventor’s perspective on forty years of MDI development and regulation. In: Dalby RN, ed. Respiratory Drug Delivery V, Phenix, Arizona: Interpharm Press, 1996; 115–24.
87. Moren F, Dolovich M, Newhouse M, Newman S. Aerosols in Medicine: Principles, Diagnosis and Ttherapy. Amsterdam: Elsevier Science Publishers; 1993.
88. Hickey A. Inhalation Aerosols, Physical and Biological Basis for Therapy, New York: Marcel Dekker Inc.; 1996.
89. Molina MJ, Rowland FS. Stratospheric sink for chlorofluoromethanes– chlorine atomic-catalysed destruction of ozone. Nature 1974; 249:810–12.
90. Vervaet C, Byron PR. Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm 1999; 186:13–30.
91. Dalby RN, Byron PR, Shepherd HR, Papadoupoulos E. CFC propellant substitution: P-134a as a potential replacement for P-12 in MDIs. Pharm Technol 1990; 14:26–33.
92. Lizio R, Damm M, Sarlikiotis AW, Bauer HH, Lehr CM. Low-Temperature Micronization of a Peptide Drug in Fluid Propellant: Case Study Cetrorelix. AAPS Pharm Sci Tech 2007; 2:1–7.
93. Green J, Gommeren E. Pharmaceutical aerosols–enhancing the metered dose inhaler. 2007.
94. Williams RO, Repka MA, Barron MK. Application of co-grinding to formulate a model pMDI suspension. Eur J Pharm Biopharm 1999; 48:131–40.
95. Young PM, Price R, Lewis D, Edge S, Traini D. Under pressure: predicting pressurized metered dose inhaler interactions using the atomic force microscope. J Colloid Interface Sci 2003; 262:298–302.
96. Ashayer R, Luckham PF, Manimaaran S, Rogueda P. Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy 2. Eur J Pharm Sci 2004; 21:533–43.
97. Traini D, Rogueda P, Young PM, Price R. Surface energy and interparticle forces correlations in model pMDI formulations. Pharm Res 2005; 22:816–25.
98. Traini D, Young PM, Rogueda P, Price R. In vitro investigation of drug particulates interactions and aerosol performance of pressurised metered dose inhalers. Pharm Res 2007; 24:125–35.
99. Traini D, Young PM, Rogueda P, Price R. Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers. Int J Pharm 2006.
100. Blondino FE, Byron PR. Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. Drug Dev Ind Pharm 1998; 24:935–45.
101. Griffiths P, Paul A, Rogueda P. Advance in non-aqueous colloids. London, UK: Royal Society of Chemistry; 2007.
102. Schultz RK, Quessy SN. Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations. 668597 ed. 1991.
103. Byron P, Blondino F. Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent. 217012 ed. 1994.
104. Purewal TS, Greenleaf DJ. Medicinal aerosol formulations. 471618 ed. 1995.
105. Stefely J, Schultz D, Schallinger L, Perman C, Leach C, Duan D. Biocompatible compounds for pharmaceutical drug delivery systems. In Properties Company MI, ed. 797803 ed. 1997.
106. Leach CL. Targeting inhaled steroids. Int J Clin Pract1998; 23–27.
107. Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T. Modulite (R): a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96:S3–8.
108. Brambilla G, Ganderton D, Garzia R, Lewis D, Meakin B, Ventura P. Modulation of aerosol clouds produced by pressurised inhalation aerosols. Int J Pharm 1999; 186:53–61.
109. Leach C, Hameister M, Tomai M, Hammerbeck D, Stefely J. Oligolactic acid (OLA) biomatrices for sustained release of asthma therapeutics. In Dalby RN, Byron PR, Farr SJ, Peart JP, eds. Respiratory Drug Delivery VII, 1st edn. Florida: Serentec Press; 2000; 75–82.
110. Stefely JS. Excipients for inhalation drug delivery: Expanding the capability of the MDI. drug delivery technology 2002; 2:62–9.
111. Stefely J, Brown B, Hammerbeck D, Stein S. Equipping the MDI for the 21st century by expanding its formulation options. In Dalby RN, Byron P, Peart JP, Farr SJ, eds. Respiratory Drug Delivery VIII, 1st ed., NC, USA: Davis Horwood International. 2002; 207–14.
112. Butz N, Porte C, Courrier H, Krafft MP, Vandamme TF. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants. Int J Pharm 2002; 238:257–69.
113. Williams RO, Liu J. Influence of formulation technique for hydroxypropyl-beta-cyclodextrin on the stability of aspirin in HFA 134a. Eur J Pharm Biopharm 1999; 47:145–52.
114. Chipps BE. Determinants of asthma and its clinical course. Ann Allergy Asthma Immunol 2004; 93:309–16.
115. Dolovich M. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care J 2000; 45:597–608.
116. Deblaquiere P, Christensen DB, Carter WB, Martin TR. Use and misuse of metered-dose inhalers by patients with chronic lung-disease–a controlled, randomized trial of 2 instruction methods. Am Rev Respir Dis 1989; 140: 910–6.
117. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH. Inhaled corticosteroids for asthma therapy–Patient compliance, devices, and inhalation technique. Chest 2000; 117:542–50.
118. Ruggins NR, Milner AD, Swarbrick A. An assessment of a new breath actuated inhaler device in acutely wheezy children. Arch Dis Childhood 1993; 68:477–80.
119. Hampson NB, Mueller MP. Reduction in patient timing errors using a breath-activated metered-dose inhaler. Chest 1994; 106:462–5.
120. Newman SP, Weisz AWB, Talaee N, Clarke SW. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique. Thorax 1991; 46:712–16.
121. Gabrio BJ, Stein SW, Velasquez DJ. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int J Pharm 1999; 186:3–12.
122. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med Deposition Clearance Eff Lung 1999; 12:151–60.
123. Newman SP. Principles of metered dose inhalers. Respir Care 2005; 50: 1177–87.
124. Lewis D, Ganderton D, Meakin B, Brambilla G. Theory and practice with solution systems. In Dalby RN, Byron PR, Peart J, Suman JD, Farr S, eds., 1st edn. Illinois: Davis Healthcare International 2004; 109–15.
125. Lewis D, Meakin B, Brambilla G. New actuators versus old: reasons and results for actuator modifications for HFA Solution MDIs. InDalby R, Byron PR, Peart J, Suman JD, Farr S, eds., 1 edn. Illinois: Davis Healthcare International Publishing. 2006; 101–10.
126. Wilby M. Increasing dose consistency of pMDIs. Drug Deliv Technol 2005; 5: 59–65.
127. Tiwari D, Goldman D, Dixit S, Malick WA, Madan PL. Compatibility evaluation of metered-dose inhaler valve elastomers with tetrafluoroethane (P134a), a non-CFC propellant. Drug Dev Ind Pharm 1998; 24:345–52.
128. Bradley L, Hunt K, Fenn T. The Performance of the EPDM Spraymiser Valve. Drug Delivery to the Lungs XV, Edimborough, UK: The Aerosol Society. 2005; 101–4.
129. Howlett D, Colwell J. Improvements in extractables from pMDI elastomer systems. Drug Delivery to the Lungs VIII The Aerosol Society. 1997; 36–8.
130. Cummings RH. Pressurized metered dose inhalers: chlorofluorocarbon to hydrofluoroalkane transition-valve performance. J Allergy Clin Immunol 1999; 104:S230–6.
131. Jinks P, Marsden S. The Development and Performance of a Fluoropolymer Lined Can for Suspension Metered Dose Inhaler Products., Portisghead, UK: The Aerosol Society. 2007; 177–80.
132. Herman CS, Riebe MT, Li-Bovet Li, Ashurst IC. Metered dose inhaler for albuterol. 831268 ed. 2000.
133. Lewis D, Ganderton D, Meakin B, Ventura P, Brambilla G, Garzia R. Pressurised metered dose inhalers (MDI). 612072 ed. 2004.
134. Traini D, Young PM, Rogueda P, Price R. The use of AFM and surface energy measurements to investigate drug-canister material interactions in a model pressurized metered dose inhaler formulation. Aerosol Sci Tech 2006; 40:227–36.
135. Gupta PK, Hickey AJ. Contemporary Approaches in Aerosolized Drug Delivery to the Lung. J Control Release 1991; 17:127–47.
136. Selroos O, Pietinalho A, Riska H. Delivery devices for inhaled asthma medication-Clinical implications of differences in effectiveness. Clin Immunotherapeut 1996; 6:273–99.
137. Newman S, Pavia D2085. Aerosol deposition in man. InNewhouse M, Dolovich M, editors. Aerosols in Medicine. Amsterdam: Elsevier. 2005; 193–218.
138. O’Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52(Suppl 2):S31–44.
139. Dalby R, Hickey A, Tiano S. Medical Devices for the Delivery of Therapeutic Aerosols to the Lungs. New York: Marcel Dekker Inc. 1996.
140. Mercer TT, Tillery MI, Chow HY. Operating characteristics of some compressed-air nebulizers. Am Ind Hygiene Assoc J 1968; 29:66.
141. Nerbrink O, Dahlback M, Hansson HC. Why do medical nebulizers differ in their output and particle-size characteristics. J Aerosol Med 1994; 7: 259–76.
142. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance–Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110:498.
143. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 1994; 106:1788–92.
144. Knoch M, Sommer E. Jet nebulizer design and function. Eur Resp Rev 2000; 10:183–6.
145. Coates AL, Ho SL. Drug administration by jet nebulization. Pediat Pulm 1998; 26:412–23.
146. Nikander K, Bisgaard H. Impact of constant and breath-synchronized nebulization on inhaled mass of nebulized budesonide in infants and children. Pediat Pulm 1999; 28:187–93.
147. Pelkonen AS, Nikander K, Turpeinen M. Jet nebulization of budesonide suspension into a neonatal ventilator circuit: Synchronized versus continuous nebulizer flow. Pediat Pulm 1997; 24:282–6.
148. LeBrun PP, deBoer AH, Gjaltema D, Hagedoorn P, Heijerman HG, Frijlink HW. Inhalation of tobramycin in cystic fibrosis. Part 1: the choice of a nebulizer. Int J Pharm 1999; 189:205–14.
149. Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995; 8:1214–21.
150. Denyer J1997. Adaptive aerosol delivery in practice. Eur Respir Rev 1997; 7: 388–9.
151. Nikander K, Denyer J, Cobos N. Compliance with nebulized budesonide in Spanish children with asthma using adaptive aerosol delivery (AAD). Am J Respir Crit Care Med 1999; 159:A119.
152. Denyer J, Ritson S, Everard ML. Aerosol delivery systems acceptable to young children improve drug delivery. Thorax 1998; 53:A55.
153. Nikander K. Drug-delivery systems. J Aerosol Med 1994; 7:S19-S24.
154. Takano H, Nakazawa M., Asai L, Itoh M. Performance of a new clinical nebuliser for drug administration based on the mesh-type ultrasonic atom-isation by elastic surface waves. J Aerosol Med 1999; 12:98.
155. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002; 47:1406–16.
156. Simon M, Gopalakrishnan V. AeroDose inhaler feasibility studies with the aerosol generator. In Dalby R, Byron PR, Farr S, Peart J, ed., 1 edn., North Carolina: Davis Horwood. 2000; 311–14.
157. Keller M, Lintz F, Walther E. Novel liquid formulation technologies as a tool to design the aerosol performance of nebulisers., London, UK: The Aerosol Society. 2001; 99–102.
158. Stangl R. The PARI eFlow: tool in the development process of a new inhaler for topic and systemic pulmonary drug delivery. Drug Delivery to the Lungs 12, London, UK: The Aerosol Society.; 2001; 107–10.
159. Smart J, Stangl R, Halsall I, Chrystyn H. TouchSpray technology: In vitro evaluation of pharmaceutical compounds. Drug Delivery to the Lungs 12, London, UK: The Aerosol Society. 2001; 103–6.
160. Grace JM, Marijnissen JCM. A Review of Liquid Atomization by Electrical Means. J Aerosol Sci 1994; 25:1005–19.
161. Bailey AG. The inhalation and deposition of charged particles within the human lung. J Electrostat 1997; 42:25–32.
162. Bailey AG, Hashish AH, Williams TJ. Drug delivery by inhalation of charged particles. J Electrostat 1998; 44:3–10.
163. Dalby R, Spallek M, Voshaar T. A review of the development of Respimat ((R)) Soft Mist (TM) Inhaler. Int J Pharm 2004; 283:1–9.
164. Schuster J, Rubsamen R, Lloyd P, Lloyd J. The AER(X)(TM) aerosol delivery system. Pharm Res 1997; 14:354–7.
165. Gonda I, Cipolla D, Farr S, et al. AERxTM: Synthesis of technologies to provide therapeutic benefits via pulmonary drug delivery. Abstracts Papers Am Chem Soc 1999; 217:U572.
166. Hong JN, Hindle M, Byron PR. Control of particle size by coagulation of novel condensation aerosols in reservoir chambers. J Aerosol Med 2002; 15: 359–68.
167. Gupta R, Hindle M, Byron P, Cox KA, McRae DD. Investigation of a novel condensation aerosol generator: solute and solvent effects. Aerosol Sci Tech 2003; 37:672–81.
168. [Anon] Current best practice for nebuliser treatment—Introduction. Thorax 1997; 52:S1.
169. [Anon] Current best practice for nebuliser treatment—Summary of guidelines. Thorax 1997; 52:S2–3.